The updated guidance for people aged 16 and over recommends using smaller amounts of intravenous fluid initially for those at risk of serious illness or death due to sepsis. Patients should be ...

The government is backing groundbreaking research to detect bowel cancer earlier and more effectively. Recent investments include £2.4 million for an AI blood test that can spot cancer with over 99% ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments.

NICE is unable to make a recommendation on nintedanib (Ofev) for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because the company did not provide an evidence ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We ...

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. Next review: This guidance will be ...

This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical ...